The uPA/uPA receptor system as a target for tumor therapy

Drug News and Perspectives

Volumn 14, Issue 7, 2001, Pages 401-411

  Sperl, S ^a   Mueller, M M ^a   Wilhelm, O G ^a   Schmitt, M ^a   Magdolen, V ^a   Moroder, L ^a  

^a Wilex Biotechnology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTOR;

CANCER THERAPY; COMPLEX FORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; REVIEW; STRUCTURE ANALYSIS;

EID: 0035211252     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2001.14.7.858423     Document Type: Review

References (85)

1. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor
2. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
3. The urokinase-type plasminogen activator system in cancer metastasis: A review
4. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
5. The plasminogen activation system in tumor growth, invasion, and metastasis
6. Recycling of the urokinase receptor upon internalization of the uPA: Serpin complexes
7. The urokinase plasminogen activator system as a novel target for tumour therapy
8. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
9. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
10. Regulation of integrin function by the urokinase receptor
11. Role of the light chain of high-molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis
12. Regulation of cell adhesion by PAI-1
13. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
14. Clinical relevance of the urokinase plasminogen activator system in breast cancer
15. Inhibition of thrombin, plasmin and plasminogen activation by amino compounds
16. Structure-activity relationship for the inhibition of plasmin and plasminogen activation by aromatic diamidines and a study of the effect of plasma proteins on the inhibition process
17. The inhibition of urokinase by aromatic diamidines
18. Synthetische inhibitoren der serinproteasen. 17. Mitteilung. Einfluss von benzamidinderivaten auf die aktivität der urokinase und den ablauf der fibrinolyse
19. Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high- and low-molecular weight urokinase and on urokinase-induced plasminogen activation
20. Aromatic amidines: Camparison of their ability to block respiratory syncytial virus-induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin
21. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice
22. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice
23. Amiloride selectively inhibits the urokinase-type plasminogen activator
24. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor
25. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model
26. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428
27. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
28. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428
29. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
30. Synthesis and structure-activity relationships of potent thrombin inhibitors - Piperazides of 3-amidinophenylalanine
31. 3-Amidinophenylalanine-based inhibitors of urokinase
32. (4-Aminomethyl)-phenylguanidine derivatives as non-peptidic highly selective inhibitors of human urokinase. X-ray crystal structure of an uPA/inhibitor complex at 1.8 A resolution
33. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite
34. Discovering novel ligands for macromolecules using X-ray crystallographic screening
35. Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors
36. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
37. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: Implications for the inhibition of factor Xa, tPA, and urokinase
38. Crystals of the urokinase type plasminogen activator variant Beta-c-uPA in complex with small-molecule inhibitors open the way towards structure-based drug design
39. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite
40. Structural basis for selectivity of a small molecule, SI-binding, submicromolar inhibitor of urokinase-type plasminogen activator
41. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator
42. Inhibition of the interaction of urokinase (uPA) with its receptor (uPAR, CD87) by synthetic peptides
43. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site
44. Solution structure of the aminoterminal fragment of urokinase-type plasminogen activator
45. Backbone dynamics of a two domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator
46. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator
47. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis
48. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue
49. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor
50. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor
51. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator: Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site
52. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
53. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice
54. Prevention of metastasis by inhibition of the urokinase receptor
55. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
56. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin
57. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointimal formation in murine and human blood vessels
58. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87)
59. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
60. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function
61. Urokinase receptor antagonists: Discovery and application to in viva models of tumor growth
62. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
63. Metalloproteases and urokinase in angiogenesis and tumor progression
64. Human prostate tumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells
65. Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells
66. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
67. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
68. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
69. Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator
70. Small-molecule approaches to inhibit the urokinase-type plasminogen activator system
71. Identification of laminin alpha 1 and beta 1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting